Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

Primary Care Education Consortium

A New Paradigm in Cardiovascular Risk Reduction in Type 2 Diabetes

Access Activity

Overview / Abstract:

Learning Objectives:
• Characterize type 2 diabetes as a cardiovascular risk factor
• Outline key aspects of care for a patient with type 2 diabetes
• Compare the classes of medications generally recommended for use in combination with metformin
• Differentiate traditional clinical outcomes trials from cardiovascular safety trials
• Describe the findings of cardiovascular safety trials demonstrating cardiovascular benefit
• Select pharmacologic treatment for use in combination with metformin that includes consideration of cardiovascular safety and benefit

This CE/CME is intended for practicing PAs, NPs, RNs and primary care clinicians engaged in the care of patients with cardiovascular risk in Type 2 Diabetes.

Credit Designation:
AMA PRA Category 1 - The Illinois Academy of Family Physicians designates this live activity, A New Paradigm Shift in CV Reduction in T2DM, for a maximum of 1.25 AMA PRA Category 1 credit™.

Method of Participation:

Upon completion of your on-site evaluation form at the end of the symposium, you will be handed a CME certificate stating the credit earned by your participation. CME credit is available for 10 weeks following the symposium if you need to send your evaluation form in at a later date. Please contact phitchman@pceconsortium.org for any questions.

NPs and PAs: The American Association of Nurse Practitioners and The American Academy of Physician Assistants accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Continuing Nursing Education:

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.25 contact hours is provided by the Postgraduate Institute for Medicine. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Request for Credit (If the evaluation is posted on CME University)
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID . Upon registering and completing the activity evaluation, your certificate will be made available immediately

Expiration

Sep 21, 2018

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Internet Point of Care (PoC), Online, Webinar / Webcast / Video

Credits / Hours

1.25 AMA PRA Category 1 credit™ and ANCC1.2 contact hour(s) designated for 0.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses

Accreditation

ACCME, ANCC

Is This Activity Certified for "Live" Credit?

YES

Presenters / Authors / Faculty

Davida Kruger, MSN, APN-BC,
BC-ADM
Division of Endocrinology, Diabetes,
Bone and Mineral Disease
Henry Ford Health System
Detroit, MI
John McGinnity, MS, PA-C,
DFAAPA
Clinical Professor
Wayne State University
Eugene Applebaum College of
Pharmacy and Health Sciences
Detroit, MI

Sponsors / Supporters / Grant Providers

This CME/CE presentation is jointly/co-provided by Illinois Academy of Family Physicians, Postgraduate Institute of Medicine and Primary Care Education Consortium, and supported by an educational grant from Novo Nordisk Inc.

Keywords / Search Terms

Primary Care Education Consortium cardiovascular risk factor type 2 diabetes medications metformin clinical outcomes cardiovascular safety trials Free CE CME Live CE CME

Access Activity

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.